Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of ASC40 (denifanstat) in moderate to severe acne vulgaris
ChiCTR2600126528Phase 3Completed
- Sponsor
- Huashan Hospital
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of denifanstat in acne vulgaris, sponsored by Huashan Hospital. Primary endpoints: Treatment-emergent adverse events (TEAEs), Serious adverse events (SAEs) and 1 more. Started Jun 2026; status: completed.
02
Drugs
denifanstat
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on ChiCTR2600126528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126528.